Mecamylamine reversal by nicotine and by a partial α7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning

Behavioural Brain Research

Volumn 143, Issue 2, 2003, Pages 159-167

  Woodruff Pak, Diana S ^a,b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Aging; Alzheimer's disease; Cognition enhancing drug; Hippocampus; Learning; Memory; Nicotinic acetylcholine receptors

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION LOSS; CONDITIONING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIZATION; EYELID REFLEX; FEMALE; HABITUATION; INJECTION; INSTRUMENTAL CONDITIONING; NONHUMAN; PAIRED ASSOCIATE LEARNING; PRIORITY JOURNAL; SPECIES COMPARISON;

EID: 0042594579     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00039-1     Document Type: Article

References (59)

1. Acri J.B., Morse D.E., Popke E.J., Grunberg N.E. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology. 114:1994;369-374.
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K.et al. Schizophrenia sensory gating and nicotinic receptors. Schizophrenia Bull. 24:1998;189-202.
3. Bancroft A., Levin E.D. Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology. 39:2000;2770-2778.
4. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten following the cholinergic hypothesis. Exp. Neurol. 163:2000;495-529.
5. Berger TW, Berry SD, Thompson RF. Role of the hippocampus in classical conditioning of aversive and appetitive behaviors. In: Isaacson RL, Pribram KH, editors. The hippocampus. New York: Plenum Press; 1986. p. 203-39.
6. Berger T.W., Thompson R.F. Neuronal plasticity in the limbic system during classical conditioning of the rabbit nictitating membrane response: I. The hippocampus. Brain Res. 145:1978;323-346.
7. Bettany J.H., Levin E.D. Ventral hippocampal alpha 7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. Pharmacol. Biochem. Behav. 70:2001;467-474.
8. Blondel A., Sanger D.J., Moser P.C. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology. 149:2000;293-305.
9. Brown R.W., Beale K.S., Jay Frye G.D. Mecamylamine blocks enhancement of reference memory but not working memory produced by post-training injection of nicotine in rats tested on the radial arm maze. Behav. Brain Res. 134:2002;259-265.
10. Brown R.W., Gonzalez C.L., Whishaw I.Q., Kolb B. Nicotine improvement of Morris water task performance after fimbria-fornix lesion is blocked by mecamylamine. Behav. Brain Res. 119:2001;185-202.
11. Coffin J.M., Woodruff-Pak D.S. Delay classical conditioning in young and older rabbits: acquisition and retention at 12 and 18 months. Behav. Neurosci. 107:1993;63-71.
12. Conroy W.G., Vernallis A.B., Berg D.K. The α5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron. 9:1992;679-691.
13. Court JA, Perry EK, Distribution of nicotinic receptors in the CNS. In: Stone TW, editor. CNS neurotransmitters and neuromodulators. London: CRC Press; 1995. p. 85-104.
14. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
15. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N.et al. A neuronal nicotinic acetylcholine receptor subunit α7 is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron. 5:1990;847-856.
16. 125-α-bungarotoxin receptor subtypes. Mol. Pharmacol. 47:1995;164-171.
17. Frazier C.J., Buhler A.V., Weiner J.L., Dunwiddie T.V. Synaptic potentials mediated via α-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J. Neurosci. 18:1998;8228-8235.
18. Gould T.J., Wehner J.M. Nicotine enhancement of contextual fear conditioning. Behav. Brain Res. 102:1999;31-39.
19. Grottick A.J., Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 117:2000;197-208.
20. Jones G., Sahakian B., Levy P., Warburton D., Gray J. Effects of acute subcutaneous nicotine on attention, information processing, and short-term memory. Psychopharmacol. (Berl.). 108:1992;485-494.
21. Kem W.R., Abbott B.C., Coates R.M. Isolation and structure of a hoplonemertine toxin. Toxicology. 9:1971;15-22.
22. Kem W.R., Mahnir V.M., Papke R.L., Lingle C.J. Anabaseine is a potent agonist on muscle and neuronal α-bungarotoxin-sensitive nicotinic receptors. Pharmacol. Exp. Ther. 283:1997;979-992.
23. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H.et al. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
24. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-431.
25. Levin E.D., Bradley A., Addy N., Sigurani N. Hippocampal alpha 7 and alpha4 beta 2 nicotinic receptors and working memory. Neuroscience. 109:2002;757-765.
26. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Chronic nicotinic stimulation and blockade effects on working memory. Behav. Pharmacol. 4:1993;179-182.
27. Levin E.D., Rose J.E. Anticholinergic sensitivity following chronic nicotine administration as measured by radial-arm maze performance in rats. Behav. Pharmacol. 1:1990;511-520.
28. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol. Neurobiol. 15:1997;193-222.
29. Lindstrom J., Schoepfer R., Conroy W., Whiting P., Das M., Saedi M.et al. The nicotinic acetylcholine receptor gene family: structure of nicotinic receptors from muscle and neurons and neuronal α-bungarotoxin-binding proteins. Adv. Exp. Med. Biol. 287:1991;255-278.
30. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
31. Moore J.W., Goodell N.A., Solomon P.R. Central cholinergic blockade by scopolamine and habituation, classical conditioning, and latent inhibition of the rabbit's nictitating membrane response. Physiol. Psychol. 4:1976;395-399.
32. Newhouse PA, Kelton M. Clinical aspects of nicotinic agents: therapeutic application in central nervous system disorders. In: Clementi F, Fornasari D, Gotti C, editors. Neuronal nicotinic receptors: experimental pharmacology. Berlin: Springer; 2000. p. 779-812.
33. Newhouse P.A., Potter A., Kelton M., Corwin J. Nicotinic treatment of Alzheimer's disease. Biol. Psychol. 49:2001;268-278.
34. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiat. 49:2001;200-210.
35. Papke R.L., Sanberg P.R., Shytle R.D. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 297:2001;646-656.
36. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Commings J.L., DeKosky S.T. Practice parameter: early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology. 56:2001;1133-1142.
37. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21:2001;1-5.
38. Powell D.A., Buchanan S.L., Hernandez L.L. Intraseptal scopolamine has differential effects on Pavlovian eye blink and heart rate conditioning. Behav. Neurosci. 99:1985;75-87.
39. Rezvani A.H., Bushnell P.J., Levin E.D. Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats. Psychopharmacol. (Berl.). 164:2002;369-375.
40. Sahakian B.J., Coull J.T. Nicotine and tetrahydroaminoacradine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug. Dev. Res. 31:1994;80-88.
41. Schildein S., Huston J.P., Schwarting R.K. Open field habituation learning is improved by nicotine and attenuated by mecamylamine administered posttrial into the nucleus accumbens. Neurobiol. Learn. Mem. 77:2002;277-290.
42. Schreiber R., Dalmus M., De Vry J. Effects of alpha4/beta2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacol. (Berl.). 159:2002;248-257.
43. Schoepfer R., Conroy W., Whiting P., Gore M., Lindstrom J. Brain α-bungarotoxin binding protein cDNAs and mAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron. 5:1990;35-48.
44. Schroder H., Wevers A. Nicotinic acetylcholine receptors in Alzheimer's disease. Alzheimer's Dis. Rev. 3:1998;20-27.
45. Solomon P.R., Gottfried K.E. The septo-hippocampal cholinergic system and classical conditioning of the rabbit's nictitating membrane response. J. Comp. Physiol. Psychol. 95:1981;322-330.
46. Solomon P.R., Levine E., Bein T., Pendlebury W.W. Disruption of classical conditioning in patients with Alzheimer's disease. Neurobiol. Aging. 12:1991;283-287.
47. Solomon P.R., Solomon S.D., Vander Schaaf E., Perry H.E. Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure. Science. 220:1983;329-331.
48. Thompson R.F. The neurobiology of learning and memory. Science. 233:1986;941-947.
49. Thompson R.F., Krupa D.J. Organization of memory traces in the mammalian brain. Ann. Rev. Neurosci. 17:1994;519-549.
50. Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J. Neurochem. 75:2000;1155-1161.
51. Weiland S., Bertrand D., Leonard S. Neuronal nicotinic acetylcholine receptors: from gene to disease. Behav. Brain Res. 113:2000;43-56.
52. West M.J., Coleman P.D., Flood D.G., Troncoso J.C. Differences in the pattern of hippocampal neuronal loss in normal aging and Alzheimer's disease. Lancet. 344:1994;769-772.
53. Woodruff-Pak D.S. Evaluation of cognition-enhancing drugs: utility of the model system of eyeblink classical conditioning. CNS Drug Rev. 1:1995;107-128.
54. Woodruff-Pak D.S., Finkbiner R.G., Sasse D.K. Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. NeuroReport. 1:1990;45-48.
55. Woodruff-Pak D.S., Li Y.-T., Hinchcliffe R.M., Port R.L. Hippocampus in delay eyeblink classical conditioning: essential for nefiracetam amelioration of learning in older rabbits. Brain Res. 747:1997;207-218.
56. Woodruff-Pak D.S., Li Y.-T., Kazmi A., Kem W.R. Nicotinic cholinergic system involvement of eyeblink classical conditioning in rabbits. Behav. Neurosci. 108:1994;486-493.
57. Woodruff-Pak D.S., Li Y.-T., Kem W.R. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645:1994;309-317.
58. Woodruff-Pak D.S., Papka M., Ramano S., Li Y.-T. Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia. Neurobiol. Aging. 17:1996;505-512.
59. Ueno K., Togashi H., Matsumoto M., Ohashi S., Saito H., Yoshioka M. Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder. J. Pharmacol. Exp. Ther. 302:2002;95-100.